Improved in vitro antitumor potential of (O,O'-Diisobutyl-ethylenediamine-N,N'-di-3-propionate)tetrachloridoplatinum(IV) complex under normoxic and hypoxic conditions

被引:9
作者
Bulatovic, Mirna [1 ]
Kaluderovic, Milena R. [2 ]
Mojic, Marija [1 ]
Zmejkovski, Bojana B. [3 ]
Hey-Hawkins, Evamarie [4 ]
Vidakovic, Melita [5 ]
Grdovic, Nevena [5 ]
Kaluderovic, Goran N. [4 ,6 ]
Mijatovic, Sanja [1 ]
Maksimovic-Ivanic, Danijela [1 ]
机构
[1] Univ Belgrade, Inst Biol Res Sinisa Stankovic, Dept Immunol, Belgrade 11060, Serbia
[2] Univ Hosp Leipzig, Dept Oral Maxillary Facial & Reconstruct Plast Su, D-04103 Leipzig, Germany
[3] Univ Belgrade, Inst Chem Technol & Met, Dept Chem, Belgrade 11000, Serbia
[4] Univ Leipzig, Inst Inorgan Chem, D-04103 Leipzig, Germany
[5] Univ Belgrade, Inst Biol Res Sinisa Stankovic, Dept Mol Biol, Belgrade 11060, Serbia
[6] Leibniz Inst Plant Biochem, Dept Bioorgan Chem, D-06120 Halle, Saale, Germany
关键词
Platinum(IV) complex; Cisplatin; ATP depletion; Mitochondrial collapse; Oxidative stress; Hypoxic conditions; PLATINUM(IV) COMPLEXES; ANTICANCER ACTIVITY; CELL-LINES; CISPLATIN; LIGANDS; SATRAPLATIN; APOPTOSIS; DEATH; CYTOTOXICITY; RESISTANCE;
D O I
10.1016/j.ejphar.2015.04.012
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
(O,O'-Diisobutyl-ethylenediamine-N,N'-di-3-propionate)tetrachloridoplatinum(IV), [PtCl4(iBu(2)eddp)]. shows an improved pharmacological profile in comparison to cisplatin. This is manifested through accelerated dying process led by necrotic cell death, reflected through mitochondrial collapse, strong ATP depletion and reactive oxygen species production. Loss of mitochondrial potential was further followed with intensive apoptosis that finalized with DNA fragmentation. Different dynamic of tumoricidal action could be partly ascribed to less affected repair mechanisms in comparison to cisplatin. Importantly, [PtCl4(iBu(2)eddp)] did not induce necrosis in primary fibroblasts suggesting different intracellular response of normal vs. tumor cells. This selectivity toward malignant phenotype is further confirmed by retained tumoricidal potential in hypoxic conditions, while cisplatin became completely inefficient. (C) 2015 Published by Elsevier B.V.
引用
收藏
页码:136 / 144
页数:9
相关论文
共 62 条
[1]
Development of organometallic (organo-transition metal) pharmaceuticals [J].
Allardyce, CS ;
Dorcier, A ;
Scolaro, C ;
Dyson, PJ .
APPLIED ORGANOMETALLIC CHEMISTRY, 2005, 19 (01) :1-10
[2]
Mechanistic insight into the cellular uptake and processing of cisplatin 30 years after its approval by FDA [J].
Arnesano, Fabio ;
Natile, Giovanni .
COORDINATION CHEMISTRY REVIEWS, 2009, 253 (15-16) :2070-2081
[3]
Mitochondria and cell death - Mechanistic aspects and methodological issues [J].
Bernardi, P ;
Scorrano, L ;
Colonna, R ;
Petronilli, V ;
Di Lisa, F .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1999, 264 (03) :687-701
[4]
Mitochondrial dysfunction in cancer [J].
Boland, Michelle L. ;
Chourasia, Aparajita H. ;
Macleod, Kay F. .
FRONTIERS IN ONCOLOGY, 2013, 3
[5]
Hypoxia and energetic tumour metabolism [J].
Brahimi-Horn, M. Christiane ;
Bellot, Gregory ;
Pouyssegur, Jacques .
CURRENT OPINION IN GENETICS & DEVELOPMENT, 2011, 21 (01) :67-72
[6]
XRCC1 is required for DNA single-strand break repair in human cells [J].
Brem, R ;
Hall, J .
NUCLEIC ACIDS RESEARCH, 2005, 33 (08) :2512-2520
[7]
Cancer Cell Metabolism: One Hallmark, Many Faces [J].
Cantor, Jason R. ;
Sabatini, David M. .
CANCER DISCOVERY, 2012, 2 (10) :881-898
[8]
Current status and future prospects for satraplatin, an oral platinum analogue [J].
Choy, Hak ;
Park, Clinton ;
Yao, Min .
CLINICAL CANCER RESEARCH, 2008, 14 (06) :1633-1638
[9]
Satraplatin: an orally available platinum analog for the treatment of cancer [J].
Choy, Hak .
EXPERT REVIEW OF ANTICANCER THERAPY, 2006, 6 (07) :973-982
[10]
The mitochondrial permeability transition pore and its role in cell death [J].
Crompton, M .
BIOCHEMICAL JOURNAL, 1999, 341 :233-249